

DAFTAR PUSTAKA

- Ahsan, F., Rahmawati, N. Y., & Alditia, F. N. (2020). *Lawan Virus Corona, Studi Nutrisi untuk Kekebalan Tubuh*. (B. Santoso, Ed.). Surabaya: Airlangga University Press.
- Alkautsar, A. (2021). Hubungan Penyakit Komorbid dengan Tingkat Keparahan Pasien Covid-19. *Jurnal Medika Hutama*, 02(01), 1488–94.
- Amgalan, Ariunzaya, and Maha Othman. "Hemostatic laboratory derangements in COVID-19 with a focus on platelet count." *Platelets* 31.6 (2020):
- Azhari, M., Health, S. H.-J. of N. and, & 2021, undefined. (2021). The Relationship of Anxiety Level With Length of Stay Corona Virus Disease 2019 (Covid-19) Patient's in Special Quarantine Bapelkes Banjarbaru. *Journal.Mbunivpress.or.Id*, 1(1), 30–37. Diambil dari <http://journal.mbunivpress.or.id/index.php/jnhe/article/view/103>
- Badan Pengawas Obat dan Makanan Republik Indonesia. (2020a). *Informatorium Obat COVID-19 di Indonesia*. Jakarta: BPOM RI.
- Badan Pengawas Obat dan Makanan Republik Indonesia. (2020b). *Perizinan, Keamanan dan Efektifitas Obat Covid19*. Jakarta: BPOM RI.
- Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., ... Lane, H. C. (2020). Remdesivir for the Treatment of Covid-19 — Final Report. *New England Journal of Medicine*, 383(19), 1813–1826. <https://doi.org/10.1056/nejmoa2007764>
- Boechat, A. L., & Dos-santos, M. C. (2020). SARS-CoV-2 and Covid-19 Immunopathogenesis, (August). <https://doi.org/10.20944/preprints202008.0020.v1>
- Burhan, E., Susanto, A. D., Nasution, S. A., Ginanjar, E., Pitoyo, C. W., Susilo, A., Santoso, A. (2020). *Pedoman Tatalaksana Covid-19*. (E. Burhan, A. D. Susanto, S. A. Nasution, E. Ginanjar, C. W. Pitoyo, A. Susilo, ... A. Santoso, Ed.), *Pedoman Tatalaksana COVID-19* (3 ed.). Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI. Diambil dari <https://www.papdi.or.id/download/983-pedoman-tatalaksana-covid-19-edisi-3-desember-2020>

- Chatterjee, S. K., Saha, S., & Munoz, M. N. M. (2020). Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19. *Frontiers in Molecular Biosciences*, 7(August), 1–11. <https://doi.org/10.3389/fmolb.2020.00196>
- Dahlan, M. S. (2018). *Langkah-Langkah Membuat Proposal Penelitian Bidang Kedokteran dan Kesehatan* (2 ed.). Jakarta: CV. Sagung Seto.
- Fajgenbaum, D. C., & June, C. H. (2020). Cytokine Storm. *New England Journal of Medicine*, 383(23), 2255–2273. <https://doi.org/10.1056/nejmra2026131>
- FK Udayana, & IDI Cabang Denpasar. (2021). *Bunga Rampai Sehat dan Bahagia Selama Menjalani Isolasi Mandiri Covid-19*. Denpasar: Penerbit Baswara Press.
- Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *BioScience Trends*, 14(1), 72–73. <https://doi.org/10.5582/BST.2020.01047>
- Grummon, Anna H., et al. "Reactions to messages about smoking, vaping and COVID-19: two national experiments." *Tobacco control* 31.3 (2022): 402-410.
- Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., ... Affiliations. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Mil Med Res*, 7(11), 2–10. <https://doi.org/10.1186/s40779-020-00240-0>
- Honardoost, M., Janani, L., Aghili, R., Emami, Z., & Khamseh, M. E. (2021). The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis. *Cerebrovascular Diseases*, 50(2), 132–140. <https://doi.org/10.1159/000513288>
- Jacques, F. H., & Apeidaile, E. (2020). Immunopathogenesis of COVID-19: Summary and Possible Interventions, (September). <https://doi.org/10.3389/fimmu.2020.564925>
- Karanasos, A., Aznaouridis, K., Latsios, G., Synetos, A., Plitaria, S., Tousoulis, D., & Toutouzas, K. (2020). Impact of smoking status on disease severity and mortality of hospitalized patients with COVID-19 infection: A systematic review and meta-analysis.

Nicotine and Tobacco Research, 22(9), 1657–1659.

<https://doi.org/10.1093/ntr/ntaa107>

Kemendes RI. (2020a). Begini Alur Pelayanan Pasien COVID-19. Diambil 22 September 2021, dari <https://www.kemkes.go.id/article/view/20101700001/begini-alur-pelayanan-pasien-covid-19.html>

Kemendes RI. (2020b). Pertanyaan dan Jawaban Terkait Covid-19. Diambil 22 September 2021, dari <https://www.kemkes.go.id/folder/view/full-content/structure-faq.html>

Kemendes RI. (2021a). *Buku Saku Protokol Tata Laksana Covid-19. Kementerian Kesehatan*. Jakarta: Kemendes RI. Diambil dari [https://www.papdi.or.id/pdfs/983/Buku Pedoman Tatalaksana COVID-19 5OP Edisi 3 2020.pdf](https://www.papdi.or.id/pdfs/983/Buku%20Pedoman%20Tatalaksana%20COVID-19%205OP%20Edisi%203%202020.pdf)

Kemendes RI. (2021b). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/4641/2021 Tentang Panduan Pelaksanaan Pemeriksaan, Pelacakan, Karantina, Dan Isolasi Dalam Rangka Percepatan Pencegahan Dan Pengendalian Coronavirus Disease 2019 (Covid-19). Jakarta: Kemendes RI.

Kemendes RI. (2021c). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/5671/2021 tentang Manajemen Klinis Tata Laksana Corona Virus Disease 2019 (Covid-19) di Fasilitas Pelayanan Kesehatan.

Kemendes RI. (2021). Pertanyaan dan Jawaban Terkait COVID-19. <https://doi.org/351.077>

Ko, W., Rolain, J., Lee, N., Chen, P., & Huang, C. (2020). Arguments in favor of remdesivir for treating SARS-CoV-2 infections. *International Journal of Antimicrobial Agents*, 55(4), 105933. <https://doi.org/10.1016/j.ijantimicag.2020.105933>

Levani, Prastya, & Mawaddatunnadila. (2021). Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi. *Jurnal Kedokteran dan Kesehatan*, 17(1), 44–57. Diambil dari <https://jurnal.umj.ac.id/index.php/JKK/article/view/6340>

Li, X., Zhong, X., Wang, Y., Zeng, X., Luo, T., & Liu, Q. (2021). Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. *PLoS ONE*, 16(5), 1–21. <https://doi.org/10.1371/journal.pone.0250602>

- Lukito, J. I. (2020). Tinjauan Antivirus untuk Terapi COVID-19. *Cdk-286*, 47(5), 340–345.
- Mohsin, F. M., Tonmon, T. T., Nahrin, R., Tithy, S. A., Ame, F. A., Ara, I., ... Hawlader, M. D. H. (2021). Association between smoking and covid-19 severity: Evidence from bangladesh. *Journal of Multidisciplinary Healthcare*, 14(June), 1923–1933. <https://doi.org/10.2147/JMDH.S317603>
- Nugraha, A., & Simanullang, R. H. (2021). Dukungan Keluarga Terhadap Tingkat Kesembuhan Pasien Covid-19 Di Ruang Isolasi Rumah Sakit Aminah 2021. *Jurnal Ilmiah Keperawatan Imelda*, 7(2), 164–169. <https://doi.org/10.52943/jikeperawatan.v7i2.661>
- Parwati, N. M. (2020). *Modul Konseling bagi Petugas Kesehatan di Puskesmas*. Yogyakarta: Penerbit ANDI.
- Ramatillah, D. L., & Isnaini, S. (2021). Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. *PLoS ONE*, 16(4 April), 1–11. <https://doi.org/10.1371/journal.pone.0250147>
- Rauf, Abdur, et al. "COVID-19 pandemic: epidemiology, etiology, conventional and non-conventional therapies." *International Journal of Environmental Research and Public Health* 17.21 (2020)
- Rejo, Iswahyuni, S., Sunaryati, S. S. H., Widiyanto, A., Darmayanti, A. T., & Atmojo, T. (2021). Efek Remdesivir pada Pasien Covid-19. *Jurnal Ilmiah Permas*, 11(2), 247–54.
- Satgas Penanganan Covid-19. (2021). Data Vaksinasi COVID-19 (Update per 20 September 2021). Diambil 22 September 2021, dari <https://covid19.go.id/p/berita/data-vaksinasi-covid-19-update-20-september-2021>
- Soedarsono. (2020). Penggunaan Antivirus pada Tatalaksana Pasien COVID-19. *Tim PINERE RSUD Dr. Soetomo*.
- Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan, H., ... & Yuniastuti, E. (2020). Coronavirus disease 2019: Tinjauan literatur terkini. *Jurnal penyakit dalam Indonesia*.

- The Indonesian Food and Drug Authority. (2020). *Informatorium of Covid-19 Drugs in Indonesia (First)*. Jakarta: The Indonesian Food and Drug Authority.
- Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., ... Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Research*, 30(3), 269–271. <https://doi.org/10.1038/s41422-020-0282-0>
- WHO. (2020). Pertanyaan Jawaban Terkait COVID-19 Untuk Publik. Diambil 30 Juli 2021, dari <https://www.who.int/indonesia/news/novel-coronavirus/qa-for-public>.
- Wu, Zunyou, and Jennifer M. McGoogan. "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention." *Jama* 323.13 (2020): 1239-1242.
- Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Wei, H. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. *Proceedings of the National Academy of Sciences of the United States of America*, 117(20), 10970–10975. <https://doi.org/10.1073/pnas.2005615117>
- Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., ... Clinical, D. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point: Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. *Clinical Infectious Diseases*, 2, 1–25.
- Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19.’ *Journal of Infection*, 80(6), 607–613. <https://doi.org/10.1016/j.jinf.2020.03.037>